Pharmacokinetics of single-agent axitinib across multiple solid tumor types

• Published in: Cancer chemotherapy and pharmacology Vol. 74; no. 6; pp. 1279 - 1289
• Main Authors: Tortorici, Michael A., Cohen, Ezra E. W., Pithavala, Yazdi K., Garrett, May, Ruiz-Garcia, Ana, Kim, Sinil, Fruehauf, John P.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2014; Springer; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic agents; Area Under Curve; Biological and medical sciences; Biological Availability; Cancer Research; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Endocrinopathies; Female; Humans; Imidazoles - pharmacokinetics; Imidazoles - therapeutic use; Indazoles - pharmacokinetics; Indazoles - therapeutic use; Male; Malignant tumors; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Models, Biological; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neoplasms - drug therapy; Nonlinear Dynamics; Oncology; Original Article; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pneumology; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors; Sex Factors; Thyroid. Thyroid axis (diseases); Tissue Distribution; Tumors; Tumors of the respiratory system and mediastinum; Young Adult; Population pharmacokinetics; Axitinib; Thyroid cancer; Non-small cell lung cancer; Melanoma; Endocrinopathy; Lung disease; Solid tumor; Tyrosine kinase inhibitor; Respiratory disease; Lung cancer; Thyroid diseases; Malignant tumor; non-small cell lung carcinoma; Indazole derivatives; Malignant melanoma; Bronchus disease; Cancer

Purpose Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors, showed antitumor activity as a single agent against several solid tumor types in Phase II and III trials. This study was conducted to evaluate axitinib pharmacokinetics across a variety of solid tumor...